SCLC, Extensive StagePhase 2NCT06620796
A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer
A Phase 2 study testing Arm 1 and second-line group in people with SCLC, Extensive Stage, run by Shanghai Pulmonary Hospital, Shanghai, China.
Trial summary
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of Ivonescimab combined with Cadonilimab and chemotherapy in extensive-stage small cell lung cancer patients. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- SCLC, Extensive Stage
- What is being tested?
- Arm 1 and second-line group
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- No sites listed yet
- Study dates
- 30 Sep 2024to 30 Sep 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent must be obtained before implementing any trial-related procedures;
- Aged 18-80 years;
- Expected survival of more than 3 months;
- histologically or cytologically confirmed ES-SCLC according to the American Veterans Cancer Association VALG staging system；
- Arm 1: subjects who have not received previous systemic therapy for extensive-stage SCLC; Or patients who had received definitive chemoradiotherapy for limited-stage small cell lung cancer but had disease progression \> 6 months later;Arm 2：ES-SCLC patients who progressed after only one PD-1/PD-L1 combination chemotherapy and had response to previous treatment (PFS ≥ 3 months), no more than two systemic chemotherapy regimens were used；
- The investigator confirms the presence of at least one measurable lesion according to RECIST 1.1 criteria;
Show all 15Show fewer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- Adequate hematologic function, defined as absolute neutrophil count (ANC) \>= 1.5 x 10^9/L, platelet count \>= 100 x 10^9/L, hemoglobin \>= 90 g/L (without transfusion history within 7 days);
- Adequate liver function, defined as total bilirubin level \<= 1.5 times the upper limit of normal (ULN) and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels \<= 2.5 times ULN in all patients, or \<= 5 times ULN in patients with liver metastases;
- Adequate renal function, defined as serum creatinine \<= 1.5 times ULN;
- Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) \<= 1.5 times ULN; for subjects receiving anticoagulant therapy, INR/PT should be within the range planned by the anticoagulant;
- Women of childbearing potential must have a negative pregnancy test within 7 days before starting treatment, and must use reliable contraceptive measures (such as intrauterine device, contraceptive pills, and condoms) during the trial and for 30 days after the end of the trial; male subjects of reproductive potential must use condoms for contraception during the trial and for 30 days after the end of the trial;
- Willingness to comply with regular follow-up visits and trial requirements.
- Participants were required to provide 10 or more unstained FFPE pathological slides (preferably newly obtained tumor tissue) archived or freshly obtained within 3 months prior to the first dose of medication. Tumor lesions used for fresh-tissue biopsy should not be used as RECIST v1.1 target lesions unless they are the only measurable lesion. The collection of archived tumor-tissue samples beyond 3 months of age was permitted, with the consent of the medical monitor, if no samples were available within 3 months of age and biopsy, as judged by the investigator, might increase the risk to the subject. If more than 10 slides were not available, some or all of the slides could be waived with investigator approval；
- Participants were required to provide approximately 10 unstained FFPE tumor tissue slides for efficacy biomarker exploration. If it cannot be provided, it can be exempted after approval from the investigator and will not affect the Participants participation in this study；
Who cannot join
- Currently participating in interventional clinical research treatment;
- For Arm 1: a) Prior immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1 /L1 antibody, anti-CTLA-4 antibody, anti-TIGIT antibody, anti-LAG-3 antibody, etc.), immune checkpoint agonists (e.g. ICOS, CD40, CD137, GITR, OX40 antibody, etc.), immune cell therapy, and any treatment targeting the tumor immune mechanism; b) previous systemic anti-angiogenic therapy, including but not limited to bevacizumab small molecule TKI, etc. For Arm 2:
- PD-1/L1 inhibitor crossover therapy: after the failure of PD-1/L1 inhibitor combined with chemotherapy, the chemotherapy regimen was changed and the original PD-1/L1 inhibitor was given again. b) Prior immunotherapy other than PD-1/L1 inhibitors, including immune checkpoint inhibitors (e.g., anti-TIGIT antibody, anti-LAG-3 antibody, etc., anti-CTLA-4 monoclonal antibody), immune checkpoint agonists (e.g. ICOS, CD40, CD137, GITR, OX40 antibody, etc.), immune cell therapy, and any treatment targeting the mechanism of tumor immune action. c) previous treatment with a taxol chemotherapeutic agent. d) previous systemic anti-angiogenic therapy, including but not limited to bevacizumab, small molecule TKI, etc.
- Imaging during the screening period showed that the tumor was surrounded by important blood vessels or had obvious necrosis or cavities, and the investigator judged that the entry of the study would cause bleeding risk.
- active autoimmune disease requiring systemic treatment within the past 2 years (e.g., with disease-modifying medications, corticosteroids, immunosuppressants). Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) is not considered a systemic treatment.
- history of noninfectious pneumonia/interstitial lung disease requiring systemic glucocorticoid treatment or current noninfectious pneumonia.
Show all 23Show fewer
- History of brain stem, meningeal metastasis, spinal cord metastasis or compression.presence of active central nervous system (CNS) metastases; Participants who had previously been treated for brain metastases (e.g., surgery, radiotherapy) were allowed if they were clinically stable for at least two weeks after treatment (calculated from the time of the first administration of the study drug) and if corticosteroids were discontinued 7 days before the administration of the study drug. Participants with untreated, asymptomatic brain metastases (i.e., no neurologic symptoms, no need for corticosteroids, no brain metastases measuring \>1.5 cm in the greatest dimension, and no substantial premetastatic edema) were eligible for enrollment
- presence of current uncontrolled coexisting medical conditions, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorder, severe active peptic ulcer disease, or gastritis, or mental illness/social condition that would limit compliance with study requirements or affect the participant\'s ability to provide written informed consent;
- previous history of myocarditis, cardiomyopathy, and malignant arrhythmia. The presence of unstable angina, myocardial infarction, congestive heart failure (New York Heart Association functional class 2 or higher), or vascular disease (e.g., aortic aneurysm at risk for rupture) that required hospitalization within 12 months before the first dose of the study drug or other cardiac impairment (e.g., uncontrolled arrhythmias, myocardial ischemia) that could affect the safety evaluation of the study drug; The patient had a history of esophagogastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months before the first dose of medication. Any arterial thromboembolic event, venous thromboembolic event of NCI CTCAE version 5.0 or higher, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy occurred 6 months before the first dose. An acute exacerbation of chronic obstructive pulmonary disease occurred within 1 month before the first dose, except for infusion-related thrombosis that had occurred for more than 4 weeks.
- history of severe bleeding tendency or coagulopathy; Clinically significant bleeding symptoms within 1 month before the first dose of medication, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or coughing up ≥1 teaspoon of blood or small blood clot or only coughing up blood without sputum, and those with blood in sputum were allowed), nasal bleeding (excluding epistaxis and retraction of nasal bleeding); Continuous antiplatelet or anticoagulant therapy had been administered within 10 days before the first dose.
- lack of resolution of toxicity from prior antineoplastic therapy, defined as failure to return to NCI CTCAE version 5.0 grade 0 or 1 or levels specified in the inclusion/exclusion criteria, with the exception of alopecia. Subjects with irreversible toxicity that was not expected to worsen with study drug administration (e.g., hearing loss) may be enrolled after consultation with the medical monitor. Subjects with long-term radiation-induced toxicity that, in the judgment of the investigator, did not recover from, may be included in the study.
- serious infection within 4 weeks before the first dose, including but not limited to coexisting conditions requiring hospitalization, sepsis, or severe pneumonia; Active infection (excluding antiviral therapy for hepatitis B or hepatitis C) that had received systemic anti-infective therapy within 2 weeks before the first dose.
- history of immunodeficiency; HIV antibody positive; Long-term use of systemic corticosteroids or other immunosuppressive agents is ongoing.
- Subjects with known active pulmonary tuberculosis should be excluded by clinical examination (e.g., sputum test, chest X-ray, etc.); Known active syphilis infection.
- history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- presence of pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring repeated drainage.
- subjects with active hepatitis B (HBsag-positive and HBV-DNA \> 500 copies /ml or higher than the lower limit of detection); Subjects with active hepatitis C (HCV antibody-positive).
- had a major surgical procedure or major trauma within 30 days before or within 30 days after the first dose (at the discretion of the investigator); Minor local procedures (excluding peripherally inserted central catheters and intravenous-access ports) had been performed within 3 days before the first dose.
- received live attenuated influenza vaccine within 30 days before the first dose or plan to receive live attenuated influenza vaccine during the study and cannot receive live attenuated influenza vaccine within 90 days after treatment after the last dose of the study drug.
- known allergy to any component of any study drug; A history of severe hypersensitivity reactions to other monoclonal antibodies was known.
- known history of mental illness, substance abuse, alcohol or drug abuse.
- pregnant or lactating women.
- The presence of any past or current medical conditions, treatments, or laboratory abnormalities that may confound the results of the study, preclude full participation in the study, or participation in the study may not be in the best interest of the subject
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of Ivonescimab combined with Cadonilimab and chemotherapy in extensive-stage small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of Ivonescimab combined with Cadonilimab for extensive-stage small cell lung cancer.
- Conditions
- SCLC, Extensive Stage
- Being tested
- Arm 1, second-line group
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Arm 1Drug
Also called AK112+AK104 group
Ivonescimab combined with Cadonilimab plus EC
second-line groupDrug
Also called AK112+AK104+paclitaxel
AK112+AK104+paclitaxel
| Study group | Role | What they receive |
|---|---|---|
| Arm1 | Experimental | Ivonescimab (20 mg/kg, IV, every 3 weeks) plus platinum-based chemotherapy (carboplatin [area under the curve (AUC) 5 mg/mL per min, IV] and etoposide [100 mg/m2, IV, D1-D3] for ES-SCLC) for up to four cycles, followed by maintenance therapy with cadonilimab (10 mg/kg, IV, every 6 weeks, D2) and Ivonescimab (20 mg/kg, IV, every 3 weeks, D1) . Receives: Drug: Arm 1 |
| Arm2 | Experimental | Cadonilimab (10 mg/kg, IV, every 6 weeks, D2) and Ivonescimab (20 mg/kg, IV, every 3 weeks, D1) plus paclitaxel [260 mg/m2, IV, D1]. Receives: Drug: second-line group |
What is being measured
The primary outcome is the main question the study is designed to answer.
6-month Progression-Free Survival (PFS) rate
The 6-month Progression-Free Survival (PFS) rate refers to the proportion of patients who are alive and without disease progression six months after starting treatment.
Measured: 6-month
Secondary outcomes (4)
Progression-free Survival
Progression-free survival measures the length of time during and after treatment that a patient lives with the disease without it progressing.
Measured: up to 60 months
objective response rate
Objective response rate represents the proportion of patients showing a predefined level of tumor shrinkage or disappearance in response to treatment.
Measured: up to 24 months
Overall Survival
Overall survival measures the length of time from the start of treatment until death from any cause, indicating the effectiveness of the treatment in prolonging patients\' lives.
Measured: up to 100 months
duration of response
Duration of response refers to the length of time during which a patient\'s tumor remains in remission or shows a positive response to treatment.
Measured: up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start30 Sep 2024 (estimated)
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SCLC, Extensive StageStudies of the same condition, open and under way.
- More trials run by Shanghai Pulmonary Hospital, Shanghai, ChinaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chunxia Su, Shanghai Pulmonary Hospital, Shanghai, China
- Investigators
- Chunxia Su, Doctor, Study chair, Shanghai Pulmonary Hospital, Shanghai, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06620796
- Sponsor's protocol ID
- 2024LY0857
- Status last verified
- Sep 2024
- First submitted
- 28 Sep 2024
- Last updated
- 1 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Public article
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT06620796
- Acronym / sponsor ID
- 2024LY0857
- Conditions
- SCLC, Extensive Stage
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, ChinaUniversity, hospital or other
- Study start
- 30 Sep 2024 (estimated)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of Ivonescimab combined with Cadonilimab and chemotherapy in extensive-stage small cell lung cancer patients. And also explore the potential biomarkers for predicting the efficacy of Ivonescimab combined with Cadonilimab for extensive-stage small cell lung cancer.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm1 | Experimental | Drug: Arm 1Ivonescimab (20 mg/kg, IV, every 3 weeks) plus platinum-based chemotherapy (carboplatin [area under the curve (AUC) 5 mg/mL per min, IV] and etoposide [100 mg/m2, IV, D1-D3] for ES-SCLC) for up to four cycles, followed by maintenance therapy with cadonilimab (10 mg/kg, IV, every 6 weeks, D2) and Ivonescimab (20 mg/kg, IV, every 3 weeks, D1) . |
| Arm2 | Experimental | Drug: second-line groupCadonilimab (10 mg/kg, IV, every 6 weeks, D2) and Ivonescimab (20 mg/kg, IV, every 3 weeks, D1) plus paclitaxel [260 mg/m2, IV, D1]. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Written informed consent must be obtained before implementing any trial-related procedures;
- Aged 18-80 years;
- Expected survival of more than 3 months;
- histologically or cytologically confirmed ES-SCLC according to the American Veterans Cancer Association VALG staging system；
- Arm 1: subjects who have not received previous systemic therapy for extensive-stage SCLC; Or patients who had received definitive chemoradiotherapy for limited-stage small cell lung cancer but had disease progression \> 6 months later;Arm 2：ES-SCLC patients who progressed after only one PD-1/PD-L1 combination chemotherapy and had response to previous treatment (PFS ≥ 3 months), no more than two systemic chemotherapy regimens were used；
Key exclusion criteria (23 listed)
- Currently participating in interventional clinical research treatment;
- For Arm 1: a) Prior immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1 /L1 antibody, anti-CTLA-4 antibody, anti-TIGIT antibody, anti-LAG-3 antibody, etc.), immune checkpoint agonists (e.g. ICOS, CD40, CD137, GITR, OX40 antibody, etc.), immune cell therapy, and any treatment targeting the tumor immune mechanism; b) previous systemic anti-angiogenic therapy, including but not limited to bevacizumab small molecule TKI, etc. For Arm 2:
- Imaging during the screening period showed that the tumor was surrounded by important blood vessels or had obvious necrosis or cavities, and the investigator judged that the entry of the study would cause bleeding risk.
- active autoimmune disease requiring systemic treatment within the past 2 years (e.g., with disease-modifying medications, corticosteroids, immunosuppressants). Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) is not considered a systemic treatment.
- history of noninfectious pneumonia/interstitial lung disease requiring systemic glucocorticoid treatment or current noninfectious pneumonia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Arm 1Also: AK112+AK104 groupIvonescimab combined with Cadonilimab plus EC | Drug | Arm1 |
| second-line groupAlso: AK112+AK104+paclitaxelAK112+AK104+paclitaxel | Drug | Arm2 |
Primary outcome
6-month Progression-Free Survival (PFS) rate
Time frame: 6-month
The 6-month Progression-Free Survival (PFS) rate refers to the proportion of patients who are alive and without disease progression six months after starting treatment.
4 secondary outcomes
Progression-free Survival
Time frame: up to 60 months
objective response rate
Time frame: up to 24 months
Overall Survival
Time frame: up to 100 months
duration of response
Time frame: up to 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2024.
- Individual participant dataSharing planned: Yes. Public article
Related trials for SCLC, Extensive Stage
Active, not recruitingPhase 3
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
RecruitingPhase 2
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Extensive-stage Small-cell Lung Cancer
Active, not recruitingPhase 2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
RecruitingPhase 2
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Small Cell Lung Cancer, SCLC
Not yet recruitingPhase 2
Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chunxia Su, Doctor study chair
Shanghai Pulmonary Hospital, Shanghai, China
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Arm 1 and second-line group in people with SCLC, Extensive Stage, run by Shanghai Pulmonary Hospital, Shanghai, China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Li Wang, Doctor (18170211997, leewang8023@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6-month Progression-Free Survival (PFS) rate (time frame: 6-month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.